Plus   Neg

Berkeley Says On Track To Meet FY20, FY25 View - Quick Facts

Berkeley Group Holdings Plc.(BKG.L), a builder of homes, neighborhoods and communities, Thursday said it is on track to meet market expectations for year ending April 30, 2020. The company is also on track to deliver long term pre-tax profit target of 3.3 billion pounds in six years in 2025.

In its trading update covering the period from November 1, 2019 to February 29, 2020, the company said it continued good trading environment and underlying demand.

Berkeley said there has been no noticeable impact on its business to date due to the global spread of Coronavirus. The ultimate impact on UK business is unknown, it said.

Further, the company said it has decided to postpone its proposed 455 million pounds increase in Shareholder Returns until there is greater clarity of operational impact of Coronavirus or COVID-19 on UK economic activity.

In view of this postponement, the General Meeting which was convened for March 18 is being adjourned indefinitely.

The company announced that a dividend of 99.32 pence per share will be paid on March 31 to Shareholders on the register on March 20.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
Follow RTT